-
FDA grants Orphan Drug Designation to DYN101 treatment
europeanpharmaceuticalreview
August 13, 2019
A treatment for Centronuclear Myopathies has received Orphan Drug Designation from the FDA and will begin Phase I/II trials.
-
Increasing Number of Diseases Causing Alopecia Boosts Treatment Market
europeanpharmaceuticalreview
August 12, 2019
The global alopecia treatment market is projected to exhibit a CAGR of 4.9 percent from 2018–2026.
-
Don't Sweat It: Hyperhydrosis Can Be Treated
drugs
August 08, 2019
There's nothing more embarrassing than sweating profusely in public places, yet one expert says many people suffer through the humiliation for decades.
-
Metastatic melanoma treatment gets Breakthrough Therapy Designation
europeanpharmaceuticalreview
August 06, 2019
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
-
Common Prostate Cancer Treatment Anti-Androgens May Increase Risk of Fatal Heart Condition
drugs
August 06, 2019
Many men with prostate cancer rely on common testosterone-blocking drugs as a part of their treatment.
-
NICE recommends Lokelma treatment for hyperkalaemia
europeanpharmaceuticalreview
August 05, 2019
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
-
Finances Affect Women's Choice of Breast Cancer Treatment: Study
drugs
August 05, 2019
Cost often influences breast cancer patients' decisions about surgery, even if they have good incomes and insurance, a new study finds.
-
Smoking May Interfere With 'Embolization' Lung Treatment
drugs
July 31, 2019
Here's yet another downside to cigarette smoking: Treatment for blood vessel abnormalities in the lungs is less likely to be successful if patients are smokers...
-
Relmada Completes Dosing of REL-1017 in Phase 2 of Treatment Resistant Depression Study
americanpharmaceuticalreview
July 30, 2019
Relmada Therapeutics announced the last subject has completed dosing with REL-1017 (dextromethadone) in the company's double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as ...
-
Stimulant Treatment Has Strong Protective Effect in ADHD
drugs
July 30, 2019
For youth with attention-deficit/hyperactivity disorder (ADHD), stimulants have strong protective effects on functional outcomes...